AlphaRx Inc. CEO Michael Lee Buys 1,000,000 Company Shares

MARKHAM, ON, Nov. 29 /PRNewswire-FirstCall/ - AlphaRx The chief executive of AlphaRx , Michael Lee, announced In a U.S. Securities and Exchange Commission filing, that he has concluded his purchase of 1,000,000 shares of his company for an average price of $0.17, increasing his holdings to about 11,327,866 shares or 13% of the company. Lee said following the purchase "I strongly believe that our share price is severely undervalued given the progress we have demonstrated in our Nanotechnology Drug Delivery Platform." 'Vansolin', Lee noted, intended for the treatment of noscomial pneumonia, is now on track to enter into human trials in 2008 and has a potential market value of US$3.6 billion. Lee concluded his comments by saying "we have four Nano products in the development pipeline with an estimated annual market sales potential of over US$6.0 billion dollars."

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

CONTACT: Nucap Investor Relations, Web: http://www.thenucap.com, E-mail:
aorlando@thenucap.com; John Young, Managing Partner, 629 Fifth Avenue,
Suite 300, Pelham, NY, 10803, (914) 924-7437, jyoung@thenucap.com,
www.thenucap.com

Back to news